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Intraplaque calcification is a prominent feature of advanced
atherosclerotic plaque development. Current clinical evidence sug-
gests that the size of calcium deposit may confer different effects
on plaque stability [1–3]. Macro-calcified deposits (CT detected)
are thought to confer plaque stability whereas micro-calcification
([18F]NaF PET detected) are thought to be a feature of high-risk
‘vulnerable’ plaques which are prone to rupture. Following on from
the emerging role of micro-calcification in high risk plaques within
the clinic [4], there is now an urgent need for preclinical
atherosclerotic models with this feature to gain mechanistic
insights and assess the impact of calcification-targeted therapies.
Using a combination of invasive and ex vivo methods, ApoE/
mice placed on an atherogenic diet have been shown to develop
intraplaque calcification [5]. Additionally, [18F]NaF PET/CT has
been used to assess the impact of exercise on calcification in
ApoE/ mice on a western diet [6]. In this study, we set out to
determine if [18F]NaF PET/CT could be used to non-invasively
detect and quantify micro-calficiation in the ApoE/ high choles-
terol diet (HCD) mouse model, and examine the temporal nature of
this process.
2. Methods
All experiments were authorized by the local University of
Edinburgh animal welfare and ethical review committee and in
accordance with the Home Office Animals (Scientific Procedures)
Act 1986. Male ApoE/ mice at 10–12 weeks of age were placed
on a HCD (D12336, Research Diets Inc., USA) for up to 12 weeks.
The animals were housed under standard 12 h light:12 h dark con-
ditions with food and water available ad libitum. In vivo PET/CT was
performed at 6 and 12 weeks post-commencement of HCD. Anaes-
thesia was induced and maintained using 1.5–2.5% isoflurane (50/
50 oxygen/nitrous oxide, 1 l/min). Body temperature was main-
tained by heated scanner bed or heated mat and monitored by rec-
tal thermometer. [18F]NaF (2.3–7.5 MBq) was administered via
intraperitoneal injection (0.2–0.3 ml). Immediately following
radiotracer administration, a 60 min scan was performed on a
nanoPET/CT (Mediso, Hungary) using 3-dimentional 1:5 mode. A
CT scan (semi-circular full trajectory, maximum field of view,
480 projections, 50 kVp, 300 ms and 1:4 binning) was acquired
for attenuation correction. Scans were reconstructed usingecommons.orgMediso’s iterative Tera-Tomo 3D reconstruction algorithm, which
includes point spread correction, and the following settings: 4 iter-
ations, 6 subsets, full detector model, low regularization, spike fil-
ter on, voxel size 0.4 mm and 400–600 keV energy window. At the
end of the PET/CT scan mice were culled and their aorta harvested
for ex vivo analysis.
Post-mortem aortas were excised from the aortic root, along the
arch (while keeping the initial portion of branches attached) and
down through the descending aorta to the abdominal aorta. Sec-
tions of the brachiocephalic trunk were wax processed, sectioned
and stained using Masson’s trichrome before the stenosis ratio
was calculated by measuring the area of plaque relative to the
lumen. Ex vivo [PET/CT] was performed at 0, 6 and 12 weeks
post-commencement of HCD using a protocol similar to that which
has been for human atherosclerotic samples [1]. Briefly, the aortas
were incubated with 103–127 kBq/ml [18F]NaF in phosphate buf-
fered saline (PBS) for 30 min and washed twice in PBS. The tissue
was then placed in the scanner and a 30 min PET scan performed
using 3-dimentional 1:5 mode. A CT scan (semi-circular full trajec-
tory, maximum field of view, 720 projections, 50 kVp, 300 ms and
1:4 binning) was acquired for attenuation correction and quantifi-
cation of macro-calcification. Scans were reconstructed using Med-
iso’s iterative Tera-Tomo 3D reconstruction algorithm as with the
in vivo studies.
PET data was analysed using PMOD version 3.8 (PMOD Tech-
nologies, Switzerland). For in vivo PET scans, micro-calcification
([18F]NaF signal) was assessed in the ascending portion of the
aortic arch by placing a volume of interest (VOI) around hotspots
of activity. If no hotspot was present, a VOI was placed in an
equivalent area of the ascending aortic arch. Background activity
in the blood was assessed by placing a VOI within the left ventri-
cle. The average [18F]NaF binding at 30–60 mins (point at which
equilibrium was reached) was then quantified and a tissue-to-
background ratio (TBRmean) was calculated. For assessment of
ex vivo samples VOIs were placed around the arch and descend-
ing aorta before the average [18F]NaF signal was quantified and
normalised to radiotracer incubation dose. Macro-calcification
was quantified on CT by thresholding the Hounsfield units to
200–5000, representing the range for calcified tissue and bone,
and averaging the top 5 voxels. All data is presented as the
mean ± standard error of the mean (SEM), with unpaired t-test
and one-way ANOVA with post-hoc Tukey’s comparison per-
formed using Graphpad Prism v6./licenses/by-nc-nd/4.0/).
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In vivo PET/CT demonstrated that micro-calcification was pre-
sent in the ascending portion of the aortic arch in all 12 week ani-
mals (Fig. 1.A). The TBRmean in this portion of the aorta was twice
that of the 6 week cohort (Fig. 1B). The progression of aortic micro-
calcification detected by in vivo imaging was then validated using
ex vivo PET/CT. ApoE/ mice culled at 10–12 weeks of age prior to
commencement of HCD (0 weeks) were used as a control group.
Histological analysis (Masson’s trichrome) on sections of the bra-
chiocephalic branch demonstrated a continuous growth of
atherosclerotic plaque over the course of 12 weeks on HCD
(Fig. 1.C). Ex vivo [18F]NaF PET/CT revealed a pattern consistent
with the in vivo data. Micro-calcification was mainly present after
12 weeks on HCD and mostly confined to the aortic arch (Fig. 1D &
E). No increase in micro-calcification was evident in the descend-
ing aorta (Fig. 1D & E). Macro-calcification was visually presentFig. 1. Temporal characterisation of atherosclerotic micro-calcification in ApoE/ HCD a
and aortic arch showing micro-calcification (broken circle) in the ascending portion of th
within the ascending aortic arch, n = 5–6. (C) Masson’s trichrome staining within the bra
on HCD, progressing to a more advanced plaque by 12 weeks HCD, n = 5–6. Scale bar = 25
arrow) and early macro-calcification (red arrows) mainly in the aortic arch after 12 wee
results are shown as the mean ± SEM, ŦŦŦŦ= p  0.0001 using an unpaired t-test; *=p <
post-hoc Tukey’s comparison. (For interpretation of the references to colour in this figu
2
on the CT scans of 3 out of the 6 animals at 12 weeks HCD and fol-
lowed a similar pattern to micro-calcification (Fig. 1E & F).
4. Discussion
In this study, we have identified a preclinical model which can
now be used as a non-invasive quantitative tool to investigate the
development of micro-calcification in atherosclerosis. We have
demonstrated that ApoE/ mice fed a HCD develop micro-calcifi-
cation within the aortic arch after 12 weeks which can be readily
detected and quantified non-invasively using [18F]NaF PET/CT.
Concurrent to this study, a similar conclusion has been demon-
strated by another group using ex vivo PET [7]. Our study is the first
report which fully characterises the temporal nature of this plaque
feature from onset, which is essential for development of preven-
tion or intervention designs. This study also presents a design
which facilitates longitudinal assessment of micro-calcificationtherosclerosis model using [18F]NaF PET/CT. (A) In vivo [18F]NaF PET/CT of the heart
e aorta within the 12 week HCD cohort. (B) Quantification of the in vivo PET signal
chiocephalic trunk indicating the presence of atherosclerotic plaques from 6 weeks
0 mm. (D) Ex vivo [18F]NaF PET/CT showing the presence of micro-calcification (white
ks HCD. (E-F) Ex vivo PET and CT quantification confirmed this pattern, n = 5–6. All
0.05, **=p  0.01, ***=p  0.001 and ****= p  0.0001 using a one-way ANOVA with
re legend, the reader is referred to the web version of this article.)
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traditional intravenous administration route for these types of
radiotracers which can be challenging over multiple imaging ses-
sions. This is in addition to a robust, non-invasive in vivo imaging
and analysis approach which can be further validated by ex vivo
molecular imaging. These mice also develop macro-calcified
lesions as has been reported in previous studies using aged
ApoE/ mice [6]. With the emerging research interest in the use
of anti-calcific agents preclinically [8] and clinically (ClinicalTri-
als.gov Identifier: NCT02132026) in the context of vascular calcifi-
cation, the field lacks a characterised and validated model for
assessment of novel therapies including the consequences of cal-
cium modulation on plaque phenotype. The model presented in
this study fulfils this unmet need.
The main limitation of this approach is the lack of ability to
directly assess plaque rupture, as murine atherosclerotic models
generally do not exhibit this feature [9]. However, this model does
allow investigations into the impact of calcium modulation on pla-
que composition which will directly inform our translational
approaches. In summary, this model can now serve as a timely
and quantifiable research tool in the assessment of intraplaque
micro-calcification in atherosclerosis.
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